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Toll/interleukin-1 (TIR)receptor-containing adapters are
critical in orchestrating the different signal transduction path-
ways following Toll-like receptor (TLR) activation. MyD88
adapter-like (Mal), also termed TIRAP, is involved in bridging
MyD88 to the receptor complex for TLR-2 and TLR4 signaling in
response to bacterial infection. We have previously reported an
interaction betweenMal and tumor necrosis factor receptor-asso-
ciated factor 6 (TRAF6) via aTRAF6-bindingmotif, the disruption
ofwhich inhibitedTLR-mediatedNF-B-luciferase reporter activ-
ity.Given therecent reportof intracellularTRAMlocalizationpro-
moting sequential signaling inTLR4 responses, we further charac-
terized Mal interaction with TRAF6, the cellular localization, and
the outcomes of disrupting this association on TLR inflammatory
responses. We found that Mal and TRAF6 directly interact in
response to TLR2 and TLR4 stimulation, although membrane
localization is not necessary to facilitate interaction. Critically,
reconstitution of murine Mal-deficient macrophages with
MalE190A, containing a mutation within the TRAF6-binding
motif, fails to reconstitute the proinflammatory response to TLR2
andTLR4 ligands comparedwithwild typeMal. Furthermore,Mal
interaction with TRAF6 mediates Ser phosphorylation of the p65
subunit of NF-B and thus controls transcriptional activation but
not nuclear translocation of NF-B. This study characterizes the
novel role forMal in facilitating thedirect recruitmentofTRAF6to
the plasma membrane, which is necessary for TLR2- and TLR4-
inducedtransactivationofNF-Bandregulationof thesubsequent
pro-inflammatory response.
Toll-like receptors (TLRs)2 recognize and respond to both
pathogen-associated molecular patterns and endogenous sig-
nals associatedwith danger (1). Upon ligand-induced dimeriza-
tion the TLRs activate, via their cytosolic Toll/IL-1 receptor
(TIR) domains, the homotypic recruitment of one ormore pro-
teins of a family of five cytosolic TIR-containing adapter pro-
teins (2). All TLRs, with the exception of TLR3, recruit MyD88
to their receptor complex, as do members of the IL-1 receptor
family. MyD88 recruits interleukin-1 receptor-associated
kinase 1 (IRAK1), IRAK4, and then TNF receptor-associated
factor 6 (TRAF6), which results in the nuclear translocation of
the prototypic inflammatory transcription factor NF-B,
termed the canonical pathway (3, 4), which encodes inflamma-
tory genes such as TNF- and IL-6. Although TLRs induce
common signaling pathways, there is specificity in recruitment
ofTIR-containing adapter proteins.MyD88 adapter-like (Mal)/
TIRAP was the second described adapter capable of mediating
NF-B activation and was responsible for signaling selectively
via TLR4 (5, 6) and TLR2 signaling (7, 8). TIR domain-contain-
ing adapter protein inducing IFN (TRIF, also known as
TICAM1) was subsequently found to mediate the MyD88-in-
dependent pathway leading toTLR4-mediated activation of the
transcription factor interferon regulatory factor 3, which regu-
lates Type I IFN production (9). Importantly, TRIF also mediates
downstream signaling from TLR3, independent of MyD88. The
TRIF-related adapter molecule (TRAM, also known as TICAM2)
specifically acts tobridgeTLR4withTRIF,whereTRAM-deficient
macrophages are ablated in their responses toTLR4activationbut
not TLR3 (10, 11).
Mal and TRAM have been described as bridging adapters,
responsible for specific recruitment of MyD88 and TRIF prox-
imal to the surface localized TLR2 and TLR4 receptor com-
plexes (10, 12, 13). Membrane localization of these bridging
adapters has further demonstrated the spatial coordination
required for transmission of MyD88 (12) and TRAM (14) sig-
nals, allowing specificity of downstream signaling mediators
that induce cytokine production. Mal acts to bridge MyD88 to
TLR2 and TLR4 specifically via its TIR domain. The recent
description of a Mal functional variant associated with protec-
tion against pnuemococcal disease, bacteremia, malaria, and
tuberculosis (15) has highlighted the potential importance of
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Mal in human disease. Furthermore, the recent depiction of the
rare TIR domain variant,Mal D96N, which is unable to interact
with MyD88 and impairs downstream TLR2/TLR4-mediated
responses (16), has emphasized the importance of protein-pro-
tein interactions in TLR-mediated signaling and highlighted
the need for a greater understanding of howMalmediates TLR-
induced inflammation.
We have previously demonstrated that Mal interacts with
TRAF6 (17) via a putative TRAF6-bindingmotif (18) that when
disrupted inhibited TLR2- and TLR4-induced NF-B activa-
tion. However the specificity and biological consequences of
this interaction were not clearly defined. Because disruption of
Mal function appears to provide a protective phenotype from
disease, we endeavored to investigate the specificity of Mal
interactionwith TRAF6, cellular localization, andwhat the bio-
logical outcomes of disrupting this interaction were on TLR-
mediated pro-inflammatory responses.
In this study, we demonstrate the direct interaction of Mal
with TRAF6 and the localization of this association to the
plasma membrane. Critically, reconstitution of Mal-deficient
macrophages with wild type Mal reconstituted transactivation
of the p65 subunit of NF-B, which was ablated with disruption
of the TRAF6-bindingmotif. Importantly, NF-B translocation
to the nucleus was not affected in these cells. Significantly,
whereas Mal-deficient macrophages reconstituted with wild
type Mal express the expected pro-inflammatory cytokines
TNF- and IL-6 in response to TLR2 and TLR4 stimulation,
cells reconstituted with a single point mutation within the
TRAF6-binding motif (MalE190A) display a significantly dis-
rupted cytokine response to TLR stimulation. Together these
studies characterize the novel role for Mal in facilitating the
direct recruitment of TRAF6 to the plasmamembrane, which is
necessary for TLR2- and TLR4-induced transactivation of
NF-B and regulation of the subsequent pro-inflammatory
response.
MATERIALS ANDMETHODS
Cell Culture and Reagents—HEK293 cells, HEK293T cells,
and murine immortalized Mal-deficient macrophages (16)
were cultured in Dulbecco’s modified Eagle’s medium supple-
mentedwith 10% fetal calf serum (Invitrogen), 2mM glutamine,
100 units/ml penicillin and maintained in a 37 °C humidified
atmosphere.HumanmonocyteTHP-1 cells weremaintained in
RPMI 1640 medium 2 mM glutamine, 100 units/ml penicillin
and maintained in a 37 °C humidified atmosphere. LPS K235
(Sigma) was repurified as described previously (19), Pam3Cys
was obtained from EMC Microcollections (Tuebingen, Ger-
many), CL-75 was from InvivoGen (San Diego, CA), CpGDNA
oligonucleotide was from GeneWorks (Adelaide, Australia),
anti-FLAG M2-agarose beads were from Sigma, and glutathi-
one-agarose beads were from Amersham Biosciences. GST,
TRAF6, and IB antibodies were sourced from Santa Cruz.
Plasmids and Protein Purification—The full-length pDC304
Mal-HA, pDC304Mal-HAN-terminal (amino acids 1–74), and
pDC304 Mal-HA TIR domains (amino acids 74–235) have
been described previously (5). The followingMal variants were
described previously: MalE190A-HA (17), Mal-GFP, Mal 4KK-
GFP (PIP2-binding domain), and Mal (1–20aa)-GFP (first 20
amino acids) (12). MalS180L-HA, MalE190A-GFP, and
Malx3-GFPmutants were generated using theQuikChange II
site-directed mutagenesis kit with Pfu Turbo (Stratagene, La
Jolla, CA) using the pDC304 Mal-HA or Mal-GFP template,
respectively. Lentiviral vectors encoding the various Mal-GFP
genewere generated by subcloning theGFP-tagged cDNA from
pEGFP-N1 into pLV-CMV. Gal4-p65(1–551) plasmid encod-
ing the full-length p65 subunit of NF-B fused to Gal4 DNA-
binding domain was a kind gift from Lienhard Schmitz (Ger-
man Cancer Research Centre, Heidelberg, Germany). The
Gal-luciferase reporter gene pFA-Jun and pFA-Elk-1 fusion
vectors for analysis of JNK and Erk1/2, respectively, were
obtained from Stratagene.
Mal-GST andMyD88-GST purification have been described
previously (20). MalE190A-GST purification was prepared the
same as for Mal-GST. GST-TRAF6-FLAG protein was trans-
formed into BL21-CodonPlusTM-RIL series Escherichia coli
(Stratagene) and grown in Luria broth. A bacterial cell culture
was grown to A600  0.5 under ampicillin selection. Protein
expression was induced with 50 M isopropyl -D-thiogalacto-
pyranoside and incubated overnight at 18 °C. Bacterial cells
were harvested and resuspended in low salt soluble KalB buffer
(50 mM Hepes, pH 7.6, 50 mM NaCl, 0.5 mM EDTA, 0.1 mM
phenylmethylsulfonyl fluoride, and 1 tablet of protease inhibi-
tor mixture (Roche Applied Science). The cells were lysed by
sonication and centrifuged, and cell pellet was resuspended in
high salt soluble buffer (50 mM Hepes, pH 7.6, 500 mM NaCl,
0.5% Triton X-100, 0.5 mM EDTA, 0.1 mM phenylmethylsulfo-
nyl fluoride, and protease inhibitor mixture (Roche Applied
Science)). Cell debris was separated by centrifugation (18,000
rpm, 4 °C). Protein purification was facilitated by affinity puri-
fication on glutathione-Sepharose and removal of GST fusion
tag by PreScissionTM (Amersham Biosciences) enzyme cleav-
age according to the manufacturer’s instructions.
Immunoprecipitation and Immunoblot Analysis—HEK293T
cells (2 106 cells/10-cmdish)were transfected using FuGENE
6 (Roche Applied Science) with the indicated plasmids where
the total amount of DNA (2.5 g/dish) was kept constant.
Twenty-four h later, the cells were lysed in KalB buffer as
described (21). The indicated antibodies (2 g) or anti-FLAG-
Sepharose beads (20l, 50% slurry)were incubatedwith the cell
lysates for 2 h, followed by the addition of 40 l of 50% protein
G slurry for 1 h. The immune complexes were precipitated,
washed, eluted by the addition of sample buffer followed by
SDS-PAGE and immunoblotted using the indicated antibodies.
For GST pulldown experiments, the lysates prepared from
HEK293T cells transfected with indicated vectors were used in
a GST pulldown assay whereby cell lysates were incubated for
2 h at 4 °C with recombinant GST fusion protein coupled to
glutathione-Sepharose. The complexes were washed three
times in lysis buffer, separated by SDS-PAGE, and immuno-
blotted as indicated in the figure legend. For endogenous
immunoprecipitation, confluent THP-1 cells (2  107) were
resuspended in 1 ml of conditioned medium, centrifuged, and
harvested as per immunoprecipitation method.
Protein samples were separated by SDS-PAGE, transferred
to nitrocellulose, and immunoblotted with the indicated anti-
bodies. Immunocomplexes were visualized by using Super-
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SignalWest Pico chemiluminescent substrate solution (Pierce)
followed by exposure to x-ray film (Hyperfilm ECL; Amersham
Biosciences) to detect chemiluminescence or visualized using
theOdyssey fluorimager (LI-COR) and probedwithAlexaFluor
680 (Molecular Probes) and IRDye800CW (Rockland, Gilberts-
ville, PA) fluorescently labeled secondary antibodies.
Confocal Imaging Analysis—HEK293 cells were cotrans-
fected with TRAF6-FLAG and fluorophore-conjugated pro-
teins at the concentrations indicated for 48 h at 32 °C. The cells
were washed in phosphate-buffered saline, fixed in 4%
paraformaldehyde, and permeabilized in 0.1% Triton X-100.
The cells were immunohistostained with anti-FLAG antibody
(Sigma) at 1:200 overnight at 4 °C and probed with Alexa Fluor
594 (Texas Red) or Alexa Fluor 488 (Green)-conjugated IgG
secondary antibody (Invitrogen). Mounted cells on coverslips
were examined with 40 oil lens objective on Leica TCS NT
upright confocal microscope (Leica Microsystems GmbH,
Welzlar, Germany) using Leica TCS NT LASAF software.
Deconvoluation and colocalization was performed using the
IMARIS software (Bit-plane AG, Zurich, Switzerland).
Luciferase Reporter Assay—HEK293 cells were seeded at 2
104 cells/well in a 96-well plate 24 h prior to transfection with
FuGENE 6.NF-B-dependent gene expressionwas determined
using the 5 B-luciferase reporter construct (Stratagene)
concomitantly with indicated vectors. Using the PathDetect
transient transfection kit (Stratagene), cotransfection of pFR-
luciferase in combinationwithGal4 fusions p65, pFA-Jun, pFA-
CHOP, or pFA-Elk-1, respectively, were used to analyze activa-
tion of p65 transactivation and MAP kinase, respectively. The
Renilla luciferase-thymidine kinase encoding plasmid (pRL-
TK) (Promega, Madison, WI) was used to normalize for trans-
fection efficiency, and pEF-BOS empty vector was used to
maintain constant DNA. Transfected cells were lysed using
passive lysis buffer (Promega) and assayed for luciferase and
Renilla activity using luciferase assay reagent (Promega). Lumi-
nescence readings were corrected for Renilla activity and
expressed as fold increases over nonstimulated control values.
ElectrophoreticMobility Shift Assay—Nuclear extracts (4g)
were incubated with 10,000 cpm of a 22-bp DNA fragment
oligonucleotide containing the NF-B consensus sequence
(Promega) that had previously been labeled with [-32P]ATP
(10 mCi mmol) (PerkinElmer Life Sciences) by T4 polynucle-
otide kinase (Promega). Incubationswere performed for 30min
at room temperature in the presence of 2 g of poly(dI-dC)
as nonspecific competitor and 10 mM Tris-HCl, pH 7.5, con-
taining 100 mM NaCl, 1 mM EDTA, 5 mM dithiothreitol, 4%
glycerol, and 100 mg/ml nuclease-free bovine serum albu-
min. The samples were subjected to electrophoresis on
native 5% (w/v) polyacrylamide gels, which were subse-
quently dried and autoradiographed.
Enzyme-linked Immunosorbent Assay and Reverse Trans-
cription-PCR—Macrophage supernatants from virally trans-
duced cells were used for enzyme-linked immunosorbent assay
to detect expression of TNF- or IL-6 with reagents from BD
PharMingen (St. Jose, CA) according to the manufacturer’s
instructions. Total cellular RNA was prepared using the
RNeasy mini kit according to the manufacturer’s instructions
(Qiagen). Two g of total RNA was treated with DNase (Pro-
mega) before cDNA synthesis using Superscript III (Invitrogen)
and random primers in a volume of 40l. cDNAwas diluted 1⁄3,
and triplicate wells were run for each sample on the 7900HT
Fast Real-Time PCR system (ABI, Foster City, CA). TaqMan
gene expression assays were conducted using premade kits
from ABI, and all of the samples were multiplexed with the
endogenous control 18 S ribosomal RNA. Relative gene expres-
sion was determined using the CT cycle threshold method.
Statistical Analysis—For statistical analysis, the data
obtained from independent experiments are presented as the
means S.D. All of the statistical analysis was performed using
GraphPad PRISM software (GraphPad Software, Inc., San
Diego, CA). The mean differences were calculated using Stu-
dent’s t test. Analysis of two independent variables was calcu-
lated using a two-way analysis of variance. The levels of signif-
icance are denoted as follows: *, p 0.05; **, p 0.01; and ***,
p 0.001.
RESULTS
Mal Interaction with TRAF6 Is Induced by TLR2 and TLR4
Stimulation—We have previously demonstrated that Mal
interacted with TRAF6 in ectopic coimmunoprecipitation
experiments; therefore we first wished to establish whether
TLR stimulation induced association between the two proteins.
As can be observed in the top set of panels in Fig. 1, TRAF6
immunoprecipitated Mal in a time-dependent manner within
10–15 min of TLR2 (Pam3Cys) stimulation of human THP-1
monocytic cells. TLR4 (LPS) activation also induced the same
effect (Fig. 1, middle set of panels), although with slightly
delayed kinetics, peaking at 20 min following stimulation.
Importantly, TLR9 (CpG DNA) stimulation failed to induce
Mal-TRAF6 interaction (Fig. 1, bottom set of panels), consistent
with Mal having a specific role in TLR2 and TLR4 signaling.
Degradation of IB was also observed in cells following stim-
ulation, confirming that the respective ligands had activated
their relevant TLR. These results demonstrate a specific inter-
action betweenMal and TRAF6 following stimulation of TLR2
and TLR4, but not TLR9, consistent with the described role for
Mal in TLR2 and TLR4 signal transduction.
Mal Interaction with TRAF6 Occurs at the Plasma
Membrane—Recently, Kagan and Medzhitov (12) demon-
strated the critical role of Mal localization to the plasma mem-
brane via an N-terminal PIP2-binding domain in TLR2 and
TLR4 signaling. Localization to the plasma membrane was
required to facilitate MyD88 recruitment to the plasma mem-
brane TLR receptor complex leading to initiation of the canon-
ical signaling pathway and subsequent activation and nuclear
translocation of NF-B. Because ectopic expression of Mal is
able to localize to themembrane (12) and activateNF-B (5, 17)
mimicking TLR stimulation, we wished to determine whether
localization ofMal and TRAF6 occurs at the plasmamembrane
or the cytosol in HEK293 cells by fluorescence microscopy.
We found that GFP-tagged Mal localized to the plasma
membrane by costaining with cholera toxin subunit B
(supplemental Fig. S1A). We next confirmed that Mal 4KK-
GFP (a kind gift from Ruslan Medzhitov, Yale University),
whichcontainspointmutationsofthePIP2-bindingregion(K15A,
K16A,K32A,K33A) and therefore disrupts Mal membrane
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24194 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 36•SEPTEMBER 4, 2009
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on M
arch 5, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
localization, and Mal 1–20-GFP, consisting of the first 20
amino acids of Mal lacking the PIP2 membrane-binding motif
and functionality, both displayed diffuse staining throughout
the cell consistent with earlier reports (12) (supplemental Fig.
S1, B and C, respectively). Ectopic expression of FLAG-tagged
TRAF6 alone was found in discrete foci scattered throughout
the cytosol and did not label the cell surface when compared
with cholera toxin subunit B staining (supplemental Fig. S1D).
To investigate whether membrane localization was required
to facilitate interaction betweenMal and TRAF6, we compared
wild type Mal association with TRAF6 to Mal 4KK-GFP,
because this variant still contains an intact TRAF6-binding
motif (Mal 188–193) but fails to localize to the membrane and
Mal 1–20-GFP,which lacks the PIP2, TIR-, andTRAF6-binding
domains. Initial three-dimensional view image analysis of coex-
pressed wild type Mal, Mal 4KK, and Mal 1–20 TRAF6 (Fig. 2,
left panel) shows that all three Mal proteins are colocalizing
withTRAF6 either at the plasmamembrane (wild typeMal; Fig.
2A) or in the cytosol (Mal 4KK and Mal 1–20; Fig. 2, B and C).
However when three-dimensional iso-surface rendition analy-
sis is applied, where the intensities of the fluorescence of each
tag are standardized to remove variance in fluorescence inten-
sity between flurophores, it becomes apparent that although
Mal and Mal 4KK colocalize in the same plane as TRAF6 and
therefore appear intensely colocalized (Fig. 2, A and B, right
panels), Mal 1–20 is clearly not colocalizing in the same plane
and therefore is not colocalized with TRAF6 (Fig. 2C, middle
and right panels). Similar colocalization ofMal and TRAF6 was
observed of Mal tagged with DsRed and TRAF6-GFP (supple-
mental Fig. S2A) or Mal-GFP and TRAF6-DsRed (supplemen-
tal Fig. S2B), indicating that the colocalization at the plasma
membrane did not result from the tag and represents a feature
of Mal and TRAF6 association itself.
To further support these findings we found that both wild
typeMal-GFP andMal 4KK-GFP, but notMal 1–20-GFP, were
able to interact with TRAF6 in coexpression immunoprecipita-
tion experiments (Fig. 2D), confirming that the GFP tag did not
affect the ability of Mal and TRAF6 to interact and that associ-
ation occurs independent of cellular localization.
Having established that interaction was not dependent on
localization, we next assessed the effects on downstream signal-
ing. We have previously found that Mal interaction with
TRAF6mediated the activation of theMAPkinase pathway and
importantly, transactivation of the p65 subunit of NF-B (17).
We therefore tested the ability of these GFP-tagged proteins to
drive NF-B activation (Fig. 2E) compared with our previously
reported results using HA-tagged Mal. Consistent with our
localization and immunoprecipitation data, both wild typeMal
andMal 4KKwere able to induce activation ofNF-B luciferase
expression, whereas Mal 1–20 failed to induce a similar
responses. Furthermore, consistent with our earlier report (17),
wild type Mal and Mal 4KK were able to induce NF-B p65
transactivation and Erk1/2 and JNK activation (Fig. 2F) via
reporter assays but critically not p38. As expected, Mal 1–20
was unable to induce activation of any pathway because of its
lack of PIP2 and TIR domains.
Taken together these results demonstrate that Mal and
TRAF6 interact either at the plasmamembrane or in the cytosol
independent of localization to the plasma membrane, suggest-
ing that the geographical constraint ofMal to the plasmamem-
brane by PIP2modificationmay be important for spatial signal-
ing or kinetics. Alternatively, TRAF6 may have a higher
preference, but not an absolute requirement for, association for
the membrane-bound Mal.
Disrupting the TRAF6-binding Motif in Mal Inhibits Mal-
TRAF6 Interaction—The requirement of an intactMal TRAF6-
bindingmotif for interactionwithTRAF6was next determined.
In our previous study we found that a single amino acid change
of E190A in Mal inhibited TLR2 and TLR4 signaling; however,
in ectopic immunoprecipitation studies, this mutation was still
able to interact with TRAF6. Therefore wewished to determine
a more specific assessment of the role of the critical glutamic
acid residue in the TRAF6-binding motif in mediating Mal
interaction with TRAF6.
To begin with we assessed Mal and TRAF6 association by
immunomicroscopy. As shown in Fig. 3, whereas it appears that
both Mal (Fig. 3A) and MalE190A (Fig. 3B) are both colocaliz-
ing with TRAF6 at the plasma membrane, three-dimensional
iso-surface rendition analysis shows that once the fluorescence
FIGURE 1.Mal immunoprecipitates with TRAF6 following TLR2 and TLR4
stimulation. Human monoctyic THP1 cells (2  107) were stimulated with
Pam3Cys (top, 100 ng/ml), LPS (middle, 100 ng/ml), or CpG-DNA (bottom, 500
nM) for indicated times. The cells were lysed, and cellular debris was removed
by centrifugation (14,000 rpm, 10min, 4 °C). The lysateswere preclearedwith
protein A-Sepharose beads, and the lysates were probed with -TRAF6
monoclonal antibody (1 g) bound to -mouse IgG beads. Detection of
immunoprecipitated (IP) endogenous Mal was analyzed by immunoblotting
(IB) with-Mal antibody (Pearl-1) and IB detectedwith-IBmonoclonal
antibody. The results are representative of three independent experiments.
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intensities are standardized, it is
apparent that Mal and TRAF6 are
colocalizing in the same plane (Fig.
3A, middle panel) and as such
appear intensely colocalized at the
plasma membrane (right panel).
Conversely, three-dimensional iso-
surface rendition shows that
MalE190A appears as discrete foci
along the plasma membrane,
whereas TRAF6 remained diffuse in
the cytosol and is not in the same
plane (Fig. 3B,middle panel) and as
such does not colocalize (right
panel). To further assess this inter-
action, we generated a mutation of
all three key residues of the TRAF6-
binding motif (PXEX(Ar/Ac)) (18)
from PPELRF3QPAERA, termed
Malx3, which interestingly, does
not appear to colocalize with TRAF6,
neither three-dimensional view nor
iso-surface rendition, and as such
does not colocalize, demonstrating
a lack of association between the
proteins (Fig. 3C). This protein also
failed to display any discernable
colocalization with TRAF6 (Fig. 3C)
as rendered by three-dimensional
iso-surface rendition colocalization,
appearing primarily throughout the
cytosol. Identical results were
observed using GFP-tagged TRAF6
and DsRed-Mal constructs (data
not shown), indicating that the
localization and the importance of
an intact TRAF6-binding motif for
Mal interaction with TRAF6 were
indicative of a function of Mal and
not the result of the fusion tag to the
proteins.
Having demonstrated an interac-
tion between Mal and TRAF6 by
microscopy, we next wished to fur-
ther support the findings above and
investigated the specificity of inter-
action and whether the association
was dependent of an intact TRAF6-
binding motif within Mal and inde-
pendent of bridging proteins. As
shown in Fig. 4A, recombinant
GST-Mal was able to specifically
immunoprecipitate ectopically ex-
pressed recombinant TRAF6 from
cellular lysates, whereas recombi-
nant GST alone was unable to rec-
ognize TRAF6. Conversely, recom-
binant GST-TRAF6 was able to
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precipitate ectopically expressed Mal from cellular lysates but
was unable to interact withMalE190A (Fig. 4B), clearly demon-
strating the requirement of an intact TRAF6-binding motif to
facilitate association. To demonstrate that the Mal interaction
with TRAF6 was direct, we next coincubated purified recombi-
nant fusion proteins of TRAF6 tagged with FLAG, in conjunc-
tion with the indicated recombinant TIR-containing proteins.
As can be observed in Fig. 4C, neither recombinant GST-
MalE190A, GST-MyD88, nor GST alone was able to be immu-
noprecipitated with TRAF6, whereas GST-Mal and TRAF6
markedly formed a complex.
Taken together, these results demonstrate that Mal and
TRAF6 directly interact at the plasma membrane, the interac-
tion dependent on an intact TRAF6-binding motif within Mal.
Importantly, these findings also suggest the interaction
betweenMal and TRAF6 are independent of post-translational
FIGURE 2. TRAF6 colocalizes with Mal regardless of localization. A–C, micrographs of HEK293 cotransfected with GFP-tagged Mal (A), Mal 4KK (B), or Mal
(1–20 aa) (C) and TRAF6-FLAG for 48h at 32 °C. Immunofluorescencemicroscopyof Z-stack images (35–50)was takenof individual cells, and three-dimensional
image reconstruction was performed using Imaris software (BitPlan). Colocalization of the Z-stack images (intense yellow) illustrates clusters of TRAF6-FLAG
(Texas Red) colocalizing with concentrated Mal-GFP in plasma membrane ruffles (arrows, right panel; bar, 8 m) following three-dimensional iso-surface
rendition. Mal4KK-GFP and Mal (1–20 aa)-GFP illustrates TRAF6 localized to the cytosol. All of the images are sections taken with a 40 oil objective lens and
are representative of at least three independent experiments where over 500 cells were examined per condition;90% of the cells displayed similar staining.
D, HEK293T cells were cotransfected with TRAF6-FLAG and GFP-tagged wild type Mal, Mal 4KK, or Mal (1–20 aa) where indicated. The cells were lysed, and
TRAF6was immunoprecipitated (IP) with-M2 FLAG-agarose beads. Detection ofMal or Mal variant-GFP proteins were analyzed by immunoblotting (IB) with
-Mal antibody. Expression of TRAF6 was verified by immunoblot analysis of cellular lysates with -FLAGM2-HRP conjugated antibody, whereas GFP-tagged
protein expression was verified by -GFP immunostaining (n 3). E, HEK293 cells were cotransfected with 5 B-luciferase promoter gene plasmid (100 ng),
concomitantly with 10 ng of either GFP-tagged Mal, Mal 4KK, Mal (1–20 aa), or HA-tagged Mal and MalE190A constructs for stimulation. Shown is the mean
relative luciferase activity S.E. for a representative experiment from three separate experiments. The readings are normalized for B-luciferase expression
over TK Renilla expression. F, HEK293 cells were cotransfected with components of the pRF-luciferase and either c-Jun (2 ng), CHOP (5 ng), Elk-1 (10 ng), or
p651–551 (10 ng) Gal4 fusion vector, in conjunction with either GFP-tagged Mal, Mal 4KK, or Mal (1–20 aa) constructs, respectively. Shown is the mean relative
luciferase activity  S.E. for a representative experiment from three separate experiments. All of the luciferase results were comparative to constitutively
expressed TK Renilla. *, p 0.05; **, p 0.01; ***, p 0.001.
FIGURE 3. Mal colocalization at the plasma membrane with TRAF6 requires an intact TRAF6 binding motif. HEK293 cells were cotransfected with
DsRed-taggedMal (A), MalE190A (B), or Malx3 (C) with TRAF6-FLAG for 48 h at 32 °C. Immunofluorescencemicroscopy of Z-stack (29–45) imageswere taken
of individual cells, and three-dimensional image reconstruction was performed using Imaris software (BitPlan). Colocalization illustrates TRAF6-FLAG colocal-
izing with Mal-DsRed in plasmamembrane ruffles (arrows, right panel; bar, 8m). MalE190A-DsRed andMalx3-DsRedmutant demonstrate plasma localiza-
tion,whereas TRAF6 is diffusely distributedwithin the cytosol (right panel; bar, 8m), andminimal colocalization is observed (right panel; bar, 10m). All of the
results are representative of three independent experiments.
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modification of either Mal or TRAF6 because of formation of a
specific complex of recombinant proteins.
Mal Association with TRAF6 Is Critical for TLR2- and TLR4-
mediated Inflammatory Responses—To establish the biological
importance of Mal and TRAF6 interaction in regulating the
immune response to TLR2 and TLR4 activation, we examined
the effect of disruption of the Mal TRAF6-binding motif on
TLR inflammatory responses. To perform these experiments
we utilized immortalized Mal-deficient macrophages. We first
established that this cell line was unresponsive to TLR2
(Pam3Cys) and TLR4 (LPS) stimulation but did respond to
TLR9 (CpGDNA), TLR7 (CL75), and TLR3 (poly(I-C)) ligands
(supplemental Fig. S3A) as assessed by TNF- production.
Immunoblotting also demonstrated the lack of Mal in these
cells (supplemental Fig. S3B). Mal-deficient macrophages were
then reconstituted with GFP-tagged Mal, MalE190A, or
Malx3 by lentiviral transduction. GFPve cells were sorted to
give a homogenous population of cells expressing GFP-tagged
proteins (supplemental Fig. S3C). Fluorescence microscopy of
cells with GFPve expression for each tagged protein was used
to verify protein expression (data not shown) and supported by
immunoblot analysis of Mal protein expression in reconsti-
tuted cells (Fig. 5A), demonstrating comparable expression lev-
els of wild type Mal, MalE190A, Malx3, and GFP alone.
Initially we wished to determine whether an intact TRAF6-
binding domain was required for NF-B nuclear translocation
to the nucleus following TLR stimulation. As can be
observed in Fig. 5, macrophages reconstituted with either
wild type Mal (lanes 1 and 4–6), MalE190A (lanes 2 and
7–9), or Malx3 (lanes 3 and 10–12), respectively, display
comparable NF-B translocation to the nucleus in response
to TLR2 (Fig. 5A), TLR4 (Fig. 5B), and TLR7 (Fig. 5C) stim-
ulation, which suggests that interaction between Mal and
TRAF6 is not required for efficient NF-B translocation via
the MyD88 canonical pathway.
We have previously reported that Mal interaction with
TRAF6 is required for transactivation of NF-B (17) and that
Mal is crucial for Ser536 phosphorylation of the p65 subunit of
NF-B (21). Because transactivation of NF-B is a critical proc-
ess in the transcriptional regulation of the inflammatory
response (22), we next investigated whether Mal interaction
with TRAF6 was critical to this response. As can be observed in
Fig. 6A, only cells reconstituted with Mal were able to demon-
strate robust Ser(P)536 p65 in response to TLR2 stimulation
with Pam3Cys (lanes 2 and 7–9) comparedwith uninfected cells
(lanes 1 and 4–6) in a time-dependent manner. Critically,
reconstitution of Mal-deficient macrophages with MalE190A
(lanes 3 and 10–12) failed to recapitulate TLR2-induced phos-
phorylation of the p65 subunit, thereby ablating transactivation
of NF-B. Notably, we observed that cells reconstituted with
Mal demonstrate TLR-induced Ser276 phosphorylation of p65,
which is absent in MalE190A reconstituted cells (compare
lanes 7–9 with lanes 10–12). Mal has not been implicated pre-
viously in this transactivation event. Interestingly, in response
to TLR4 stimulation,MalE190A reconstituted cells display par-
tially restored p65 Ser536 or Ser276 phosphorylation (Fig. 6B),
perhaps because of compensation by the MyD88-independent
pathway.
FIGURE 4.Mal directly interacts with TRAF6 via an intact TRAF6-binding
motif.A, HEK293T cellswere transiently transfectedwith FLAG-taggedTRAF6
(1.25 g) for 24 h. The cells were lysed and immunoprecipitated (IP) with
either 1 g of recombinant GST-Mal or GST protein. Mal interacting com-
plexes were visualized by immunoblotting (IB) with -FLAG antibody to rep-
resent TRAF6. Expression of TRAF6 in transiently transfected cells was con-
firmed by immunoblot of cell lysates with -FLAG antibody. B, HEK293T cells
were transfected with either HA-tagged wild type Mal or the Mal mutated
TRAF6-binding motif, MalE190A (1.25 g, respectively) where indicated. The
cells were lysed and immunoprecipitated with 1 g of recombinant TRAF6-
GST. TRAF6-GST protein immunocomplexed with ectopically expressed wild
type Mal but not with MalE190A when immunoblotted with -HA antibody.
Mal protein expression was confirmed by immunoblot analysis of cell lysates
using -HA antibody to detect Mal-HA. C, recombinant TRAF6-FLAG protein
(0.75 g) interacts specifically with recombinant GST-Mal (1.5 g) but not
with GST-fused MyD88 or MalE190A protein in an in vitro binding assay.
TRAF6 immunocomplexes were precipitated using -M2 FLAG beads in a
high salt (400 mM) phosphate-buffered saline buffer and immunoblotted
with-GST antibody to detect interacting proteins. Recombinant proteins
were confirmed by immunoblot analysis of inputs with their indicated
antibodies. All of the results are representative of three independent
experiments.
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To determine whether Mal-TRAF6-mediated NF-B trans-
activation plays a role in the inflammatory cytokine response to
TLR stimulation, we next investigated cytokine expression in
reconstituted Mal-deficient macrophages. Mal-deficient mac-
rophages were reconstituted with wild typeMal, MalE190A, or
Malx3 and stimulatedwith LPS, Pam3Cys, or the TLR7/8 ago-
nist CL-75 (23) to induce IL-6 or TNF- mRNA and protein
gene expression. Although reconstitution with Mal was able to
mediate potent IL-6 (Fig. 7, A and D) and TNF- (Fig. 7, B and
E) expression compared with the GFP reconstituted or nonin-
fected cells alone, both MalE190A and Malx3 displayed sig-
nificantly inhibited TLR2 and TLR4 proinflammatory
responses. Importantly, as expected, TLR7/8 stimulation
induced a robust response with all constructs and was inde-
pendent of the absence or presence of Mal. Significantly, TLR4
induction of IFN mRNA was also not affected either in the
presence or the absence of Mal (Fig. 7C), consistent with Mal-
independent TLR4-induced IFN expression (8).
Taken together, these results clearly demonstrate the critical
role Mal interaction with TRAF6 plays in generating the pro-
inflammatory response as a consequence of TLR2 and TLR4
activation and that the mechanism is via a pathway of NF-B
transactivation, independent of the canonical MyD88-depend-
ent NF-B nuclear translocation.
DISCUSSION
In this study we have extended and characterized our earlier
finding that the novel interaction of Mal with TRAF6 has a
critical role in TLR2- and TLR4-induced inflammatory
responses. Localization studies demonstrate that the geograph-
ical constraint of Mal to the plasma membrane may be impor-
tant in the spatial control of Mal-mediated signaling. Signifi-
cantly, the data presented characterize the direct interaction
between Mal and TRAF6, which regulates transactivation of
the p65 subunit of NF-B but does not affect NF-B nuclear
translocation. The association of Mal and TRAF6 therefore
appears to control the transcriptional expression of NF-B-
dependent pro-inflammatory cytokines. Reconstitution of
Mal-deficient macrophages with MalE190A containing a
FIGURE 5. Mal interaction with TRAF6 does not affect NF-B nuclear
translocation in response to TLR stimulation. A, virally transduced GFP-
positive populations for each indicated gene were gated, sorted for 90%
GFP positive population, and then seeded at a concentration of 3 104 cells/
well 24 h prior to lysis in KalB buffer. Cellular debris was removed by centrif-
ugation (13,000 rpm, 10 min, 4 °C), and equal protein was loaded onto SDS-
PAGE and transferred to nitrocellulose, and the relative expression of viral
reconstituted immortalizedMal-deficient macrophages assessed for GFP-ex-
pressing proteins by immunoblot of cell lysates with -GFP antibody. Recon-
stituted Mal-deficient macrophages expressing the indicated genes were
seeded at 1 104 cells/ml in 6-well plates 72 h prior to stimulation with TLR2
ligand Pam3Cys (B, 10 ng/ml), TLR4 ligand LPS (C, 10 ng/ml), or TLR7 ligand
CL-75 (D, 0.5 g/ml) for the indicated times. Nuclear extracts (4 g) were
prepared, incubatedwith -32P-labeled NF-BDNA probe, and analyzed by a
6% native gel. Binding to the NF-B probe was observed in all stimulated
virally reconstituted nuclear extracts (lanes 1–12) but onlyweakly observed in
nonstimulated cells (lanes 1–3). Uninfected stimulated extracts observed
binding from treatment with LPS (C) and CL-75 (D) but not from Pam3Cys (B)
(lanes 13–15). Unbound free NF-B probe was shown in lower panel of B. The
results are representative of two independent experiments.
FIGURE 6. Mal interaction with TRAF6 is required for TLR2- and TLR4-
mediated transactivation of the p65 subunit of NF-B. ImmortalizedMal-
deficientmacrophageswere virally reconstitutedwith eitherGFP-taggedMal
(lanes 2 and 7–9) or MalE190A (lanes 3 and 10–12) as described previously in
Fig. 5. GFP-positive populations were challenged with either 10 ng/ml of
Pam3Cys (A) or LPS (B) for indicated time points and lysed, and protein was
separated by SDS-PAGE followed by immunoblot (IB) for p65, p65 Ser276, or
p65 Ser536 phosphorylation where indicated. The results represent three
independent experiments.
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point mutation within the TRAF6-binding motif signifi-
cantly inhibits both TLR2- and TLR4-mediated inflamma-
tory responses compared with wild type Mal. These results
describe a specific role for Mal in TLR signaling and identify
a direct interaction betweenMal and the key signaling medi-
ator TRAF6 that is separate from that of acting simply as a
bridging adapter for MyD88 signaling.
The importance of Mal in TLR-mediated signal transduc-
tion in human disease was suggested by the recent descrip-
tion of the S180L functional variant and its association with
protection against pneumoccal disease, tuberculosis,
malaria, bacteremia, and systemic lupus erythematosus (15,
24). We found no effect of this variant on the ability of Mal to
recruit TRAF6 (data not shown); however, our studies with
MalE190A and those by Hill and co-workers (15) combined
with the inability of the rare Mal D96N SNP to interact with
MyD88 (16) highlight the fact that structural modifications
to Mal can have important implications in the formation of
the plasma membrane proximal signaling complex. Interest-
ingly, whereas Mal has been reported to undergo Tyr phos-
phorylation (25, 26), caspase-1-mediated cleavage (27), and
now the physiological impact of the S180L variant, none of
these events altered the ability ofMal to interact with TRAF6
in immunoprecipitation experiments because ectopically
expressed single amino substitution variants were still rec-
ognized by recombinant TRAF6 (data not shown), which
combined with the direct interaction of the recombinant
Mal and TRAF6 proteins strongly suggests that post-trans-
lational modification is not required for the interaction to
occur. This suggests therefore that there is still more to be
understood as to the signaling capabilities of Mal. Critically,
this study illustrates the importance of a single amino acid
substitution within the critical TRAF6-binding motif of Mal
and demonstrates how the immune response to TLR2 and
TLR4 is profoundly affected. Consequently, Mal does not act
solely as a bridging adapter, facilitating MyD88 recruitment
to the membrane proximal receptor complex, but directly
recruits TRAF6 to the plasma membrane to regulate NF-B
transactivation and ultimately transcriptional activation of
the inflammatory response, independent of NF-B nuclear
translocation.
Interestingly, the TRAF6-binding motif in Mal is situated
within its TIR domain raising the possibility of MyD88 and
TRAF6 competing for binding sites. A recent paper by Ohnishi
et al. (28) demonstrated through complex structural modeling
that twoMal proteins boundMyD88 based on residues respon-
sible for TIR-TIR interaction. Their model suggested that
MyD88-TIR binding would not interfere with interactions
between Mal-TIR and TLR4, TLR2, or TRAF-6 because the
Glu190 inMal was distal to theMal-MyD88 interaction surface.
This model is therefore suggestive of the formation of a signal-
ing complex comprising TLR4, Mal, TRAF6, and MyD88 to
initiate the signaling cascade.
It has previously been demonstrated that the myristoyla-
tion sequence in the N terminus of TRAM is critical for its
plasma localization and the ability to mediate TLR4 signal-
ing (29). Kagan et al. (14) demonstrated that TRAM also
requires further phosophoinositide modification that facili-
tates recruitment of TRIF and subsequently TRAF3 to the
complex to promote other signaling pathways. This modifi-
cation or geographical constraint appears to provide the
TRAMTRIF complex with the opportunity to specifically
recruit TRAF3, an adapter required for induction of IFN.
This description of “spatial” signaling control of TRAM (14,
30) and its geographical restriction to the endosomal mem-
brane as a means of organizing and coordinating the two
TLR4 adapter systems may have similarities to what we have
observed in this study for Mal. Consequently, selective
recruitment of TRAF family members to TIR adapter pro-
teins because of localizationmay provide spatial control over
signaling, which integrates signals and allows coordination
of NF-B, MAP kinase, and interferon regulatory factor sig-
naling pathways. Indeed our study found that the Mal 4KK
variant that was unable to localize to the plasma membrane
could still activate MAP kinases and NF-B transactivation
commensurate with wild type Mal, suggesting that mem-
brane localization was not critical for mediating this aspect
of Mal function. Analogous to that observed with TRAM,
Mal localization to the membrane via PIP2 activation may
provide an optimal platform forMal and TRAF6 to associate,
which would be distinct from theMyD88IRAKTRAF6 com-
plex utilized by other TIR signaling pathways. The experi-
ments described herein suggest that Mal interaction with
TRAF6 does not affect MyD88-dependent pathway signal
transduction leading to NF-B nuclear translocation. How-
ever, the nuclear translocated NF-B would not appear to
undergo transactivation without the Mal-TRAF6 interac-
tion. It would appear that Mal interaction with TRAF6 is
implicit in transactivation of the p65 subunit of NF-B,
seemingly via theMAP kinase pathway (17). Thus the plasma
membrane localization of Mal and TRAM appears to allow
the spatial recruitment of specific signaling components
and, as such, coordinating downstream signaling events (30)
analogous to that described with TRAM and TRAF3 to reg-
ulate IFN induction.
Using complementation experiments in Mal-deficient
macrophages, we were able to clearly demonstrate the
importance of interaction between Mal and TRAF6 for a
robust inflammatory response to TLR2 and TLR4 ligands.
Disruption of the TRAF6-binding motif in Mal inhibited
both NF-B transactivation (phospho-p65 Ser276 and Ser536)
(22) and significantly ablated cytokine gene expression and
FIGURE7.AdisruptedTRAF6-bindingdomain inMal inhibits TLR2- andTLR4-mediatedNF-Bproinflammatory responses.Mal-deficientmacrophages
were reconstitutedwith either no virus, GFP, GFP-taggedMal,MalE190A, orMalx3 as indicatedwere seededat 3104 cells/well 72hprior to stimulationwith
10 ng/ml of Pam3Cys, LPS, or CL-75 (0.5 g/ml) ligand, respectively. RNA was extracted frommacrophages after 3 h of challenge, and mRNA induction levels
of IL-6 (A), TNF- (B), and IFN (C) were measured using quantitative real time PCR where the relative abundance was compared with 18 S levels. The
supernatants were collected from macrophages 24 h after stimulation and assessed for IL-6 (D) or TNF- (E) expression by enzyme-linked immunosorbent
assay.Mal variants lacking an intact TRAF6-bindingmotif demonstrate defective for TLR2 andTLR4-inducedpro-inflammatory cytokine expression. The results
are the means S.E. of three experiments. *, p 0.05; **, p 0.01; ***, p 0.001.
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production in response to TLR2 and TLR4 stimulation.
Interestingly, whereas the TRAF6-binding motif is impor-
tant for some of the functionality of Mal, all three critical
amino acids of the motif required mutation to significantly
inhibit LPS-mediated TNF- production. This result sug-
gests that other pathways may play a role in TLR4-induced
TNF- secretion. This disparity in effect may be a combina-
tion of the complexity of TLR4 signaling (i.e. MyD88-de-
pendent and MyD88-independent signaling) combined with
the intricacies of TNF secretion requiring expression, traf-
ficking, and transmembrane cleavage, which may explain the
discrepancy between these results. Interestingly, Baltimore
and co-workers (31) have suggested that TNF- is expressed
by the MyD88-independent pathway via interferon regula-
tory factor 3, which was time-dependent. Additionally, p38
has been shown to play a role in regulating both TNF-
message stability and protein expression (32, 33). We have
described previously that Mal interaction with TRAF6medi-
ates Erk1/2 and JNK activation (17), but not p38, which may
explain the discrepancy that the MalE190A mutant is still
able to induce TNF- expression. Moreover, we also dem-
onstrated that reconstitution of Mal-deficient cells with
MalE190A did not affect the ability of TLR4 to drive the
MyD88-independent pathway (as witnessed by a lack of an
effect on IFN induction). Therefore, it may be possible that
inhibition of TNF- mRNA expression by MalE190A repre-
sents “early” activation, but the “late” MyD88-independent
response has compensated for this inhibition.
Overall, this study clearly demonstrates a critical role for
Mal in TLR2- and TLR4-mediated inflammatory responses
that are novel to its role as a bridging adapter for MyD88.
Mal regulation of the transcriptional control of NF-B via
TRAF6 interaction and the subsequent expression of inflam-
matory cytokines is a key regulatory step in TLR2 and TLR4
inflammatory responses. This interaction allows activation
of both the MyD88-dependent canonical and Mal-TRAF6-
dependent transactivation pathways, culminating in the
coordinated translocation and subsequent transactivation of
NF-B, both of which are critical to production of pro-in-
flammatory cytokines.
Significantly, a single point mutation within the TRAF6-
binding motif of Mal is able to potently inhibit the pro-in-
flammatory response to TLR2 and TLR4 ligands, the primary
response mechanism for Gram-positive and Gram-negative
bacteria. This study identifies Mal as a key regulator of TLR2
and TLR4 signal transduction via a novel interaction with
TRAF6, the possible disruption of which may provide a puta-
tive specific therapeutic intervention for TLR2- and TLR4-me-
diated inflammatory diseases without impacting on MyD88-
dependent or TRIF/TRAM-dependent signaling pathways.
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